Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

The treatment of patients affected by non-small cell lung cancer (NSCLC) has been revolutionised by the discovery of druggable mutations. ROS1 (c-ros oncogene) is one gene with druggable mutations in NSCLC. ROS1 is currently targeted by several specific tyrosine kinase inhibitors (TKIs), but only tw...

Full description

Bibliographic Details
Main Authors: Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
lung cancer
solid tumours
crizotinib
toxicity
TKI inhibitors
resistance mechanisms
Online Access:https://www.mdpi.com/2072-6694/12/11/3293

Internet

https://www.mdpi.com/2072-6694/12/11/3293

Similar Items